LOH, LST, and TAI Profiles in Solid Tumors Harboring Pathogenic or Likely Pathogenic BRCA1/2 Variants: An Exploratory Study
4 affiliations
- 1Department of Medical Oncology, Aydin City Hospital, Efeler, Aydin 09020, Türkiye
- 2Department of Medical Pathology, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, Türkiye
- 3Department of Medical Genetics, School of Medicine, Aydin Adnan Menderes University, Efeler, Aydin 09010, Türkiye
- 4Faculty of Engineering, Aydin Adnan Menderes University, Efeler, Aydin 09010, Türkiye
Abstract
Homologous recombination deficiency (HRD) is a critical indicator of genomic instability; however, the composite HRD score may not reflect the distribution of distinct genomic scar components underlying this phenotype. In this exploratory study, we compared the absolute and relative contributions of loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allelic imbalance (TAI) among solid tumors harboring pathogenic or likely pathogenic (P/LP) variants in BRCA1 or BRCA2. This retrospective study included 76 patients with solid tumors who underwent HRD testing between January 2023 and January 2026. P/LP variants in homologous recombination repair (HRR) genes, alongside LOH, LST, and TAI scores, were evaluated. The composite HRD score was calculated as LOH + LST + TAI, with values ≥ 56 defined as HRD-positive. Additionally, the relative contribution of each scar component to the total HRD score was determined. Given the small sizes of the BRCA1-only and BRCA2-only subgroups and the heterogeneity of the overall cohort, all gene-group comparisons were considered exploratory and hypothesis-generating. Overall, 21.1% of the cohort was HRD-positive. Patients harboring BRCA1/2 P/LP variants displayed a significantly higher median HRD score compared to non-carriers (47.0 vs. 30.0; p = 0.016). When comparing patients with tumors harboring BRCA1-only (n = 9) and BRCA2-only (n = 10) P/LP variants, LOH was higher in the BRCA2 group (19.0 vs. 5.0; p = 0.036); however, this difference did not retain statistical significance following false discovery rate (FDR) adjustment (q = 0.108). In an exploratory sensitivity analysis restricted to breast and ovarian tumors (BRCA1-only, n = 5; BRCA2-only, n = 9), the LOH/HRD ratio was higher in the BRCA2 group (0.301 vs. 0.000; p = 0.026; q = 0.039), whereas the LST/HRD ratio was higher in the BRCA1 group (0.488 vs. 0.310; p = 0.019; q = 0.039). These estimates were based on very small subgroups and should therefore be interpreted cautiously. This exploratory analysis identified differences in the relative distributions of LOH and LST between tumors harboring BRCA1-only and BRCA2-only P/LP variants, particularly in the breast/ovarian subset. However, the small and heterogeneous subgroups, together with the absence of systematic assessment of biallelic BRCA1/2 inactivation, preclude gene-specific or mechanistic conclusions. These observations should be regarded as hypothesis-generating and require validation in larger, tumor-specific, independent cohorts.
Related
- Progressive behavioral and cognitive decline in Drosophila harboring AD-associated APOE4 variants
- Base Editing as a Therapeutic Strategy for Autosomal Dominant Tubulointerstitial Kidney Disease caused by Pathogenic UMOD Variants
- Population-specific differences in ClinVar pathogenic and likely pathogenic variants of epilepsy-associated genes between East Asian and non-finnish European populations: a nucleotide-resolved gnomAD v4.1.1 analysis
- Identifying Putative Pathogenic Non-Coding Variants in Unresolved Rare Disease Patients Using Topologically Associated Domains
- Decoding super-enhancer regulatory grammar and pathogenic gain-of-function variants directly from DNA sequence
BibTeX
@article{erdogdu2026profiles,
title = {{LOH, LST, and TAI Profiles in Solid Tumors Harboring Pathogenic or Likely Pathogenic BRCA1/2 Variants: An Exploratory Study}},
author = {Suleyman Erdogdu and Busra Ekinci and Seda Orenay-Boyacioglu and Olcay Boyacioglu and Ibrahim Halil Erdogdu and Ibrahim Meteoglu},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198851},
url = {https://www.mdpi.com/1422-0067/27/19/8851},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - LOH, LST, and TAI Profiles in Solid Tumors Harboring Pathogenic or Likely Pathogenic BRCA1/2 Variants: An Exploratory Study
AU - Suleyman Erdogdu
AU - Busra Ekinci
AU - Seda Orenay-Boyacioglu
AU - Olcay Boyacioglu
AU - Ibrahim Halil Erdogdu
AU - Ibrahim Meteoglu
PY - 2026
DA - 2026/10/04
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198851
UR - https://www.mdpi.com/1422-0067/27/19/8851
AB - Homologous recombination deficiency (HRD) is a critical indicator of genomic instability; however, the composite HRD score may not reflect the distribution of distinct genomic scar components underlying this phenotype. In this exploratory study, we compared the absolute and relative contributions of loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allelic imbalance (TAI) among solid tumors harboring pathogenic or likely pathogenic (P/LP) variants in BRCA1 or BRCA2. This retrospective study included 76 patients with solid tumors who underwent HRD testing between January 2023 and January 2026. P/LP variants in homologous recombination repair (HRR) genes, alongside LOH, LST, and TAI scores, were evaluated. The composite HRD score was calculated as LOH + LST + TAI, with values ≥ 56 defined as HRD-positive. Additionally, the relative contribution of each scar component to the total HRD score was determined. Given the small sizes of the BRCA1-only and BRCA2-only subgroups and the heterogeneity of the overall cohort, all gene-group comparisons were considered exploratory and hypothesis-generating. Overall, 21.1% of the cohort was HRD-positive. Patients harboring BRCA1/2 P/LP variants displayed a significantly higher median HRD score compared to non-carriers (47.0 vs. 30.0; p = 0.016). When comparing patients with tumors harboring BRCA1-only (n = 9) and BRCA2-only (n = 10) P/LP variants, LOH was higher in the BRCA2 group (19.0 vs. 5.0; p = 0.036); however, this difference did not retain statistical significance following false discovery rate (FDR) adjustment (q = 0.108). In an exploratory sensitivity analysis restricted to breast and ovarian tumors (BRCA1-only, n = 5; BRCA2-only, n = 9), the LOH/HRD ratio was higher in the BRCA2 group (0.301 vs. 0.000; p = 0.026; q = 0.039), whereas the LST/HRD ratio was higher in the BRCA1 group (0.488 vs. 0.310; p = 0.019; q = 0.039). These estimates were based on very small subgroups and should therefore be interpreted cautiously. This exploratory analysis identified differences in the relative distributions of LOH and LST between tumors harboring BRCA1-only and BRCA2-only P/LP variants, particularly in the breast/ovarian subset. However, the small and heterogeneous subgroups, together with the absence of systematic assessment of biallelic BRCA1/2 inactivation, preclude gene-specific or mechanistic conclusions. These observations should be regarded as hypothesis-generating and require validation in larger, tumor-specific, independent cohorts.
SN - 1422-0067
ER -